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http://dx.doi.org/10.1016/j.pedneo.2Background: The indications for ductus arteriosus ligation in very-low-birth-weight infants
(VLBWIs) with persistent ductus arteriosus (PDA) are unclear. Increased left ventricular end-
diastolic dimension (LVDd) is commonly found in patients with PDA. Here, the enlargement
of LVDd in term and preterm neonates without congenital heart disease was estimated by
two-dimensional echocardiography.
Methods: The value of the measured LVDd was divided by the normal LVDd as an index (LVDd
ratio) to compare 30 patients who underwent PDA ligation with 30 patients treated with indo-
methacin and 30 patients who did not undergo radical therapy.
Results: An LVDd ratio between 122% and 197% (mean, 142%) was considered to be an indica-
tion for the ligation procedure. The proportion of patients exceeding 130% in the LVDd ratio
was 87% (26/30) in those patients who underwent ligation. Catecholamines and/or vasodilators
were required in 83% patients for the treatment of low ejection fraction or hypertension after
operations, suggesting that patients had been in preload and/or afterload remodeling failure
during the operation. The percentage of patients with less than 115% in the LVDd ratio was 90%
in the non-radical-therapy patients. The LVDd ratios of 130% and 115% were regarded as cut-off
values for surgical ligation and indomethacin treatment.
Conclusion: The LVDd ratio is a useful measure to determine the treatment of VLBWIs with
PDA.
Copyright ª 2013, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
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Table 1 Characteristics of 90 patients.
Groups Ligation Indomethacin Control
No. of patients 30 30 30
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The treatment for very-low-birth-weight infants (VLBWIs)
with persistent ductus arteriosus (PDA) is limited to indo-
methacin administration or surgical ligation of the ductus
arteriosus (DA). Indications for treatment are based on
several criteria applied singly or in combinations, including
increased end-diastolic flow of the left pulmonary artery
(LPA end), increased left atrium to ascending aorta diam-
eter ratio (LA/Ao ratio) on echocardiography, increased
cardiothoracic ratio on X-ray, increased heart rate,
decreased diastolic blood pressure, decreased urinary
output, and increased brain natriuretic peptide value.
However, the indications for the treatment of VLBWIs with
PDA have not been established.
Echocardiography has long been used to assess heart size
in children. In this study, two-dimensional echocardiogra-
phy with height as an index was used to examine left ven-
tricular end-diastolic dimension (LVDd) and its rate of
increase in neonates, including premature neonates.1,2 In
PDA patients, the flow through the DA increases mitral
valve flow causing increased LVDd. We therefore compared
the LVDd values in PDA patients to those of healthy patients
and used the difference (LVDd ratio) as an index for PDA
severity.
We had three objectives in this study: (1) to determine
the usefulness of the LVDd ratio in patients with PDA
compared to that of LPA-end and LA/Ao ratio; (2) to
determine the cut-off value of the LVDd ratio for the se-
lection of different treatment strategies; and (3) to pro-
pose a new treatment algorithm based on the LVDd ratio as
an index in VLBWI with PDA.Sex (male/female) 11/19 11/19 12/18
Gestational age (wk) 26.6  1.7 27.1  1.8 27.0  1.6
Birth weight (g) 891  277 969  243 958  2492. Materials and methods
AGA/LGA 26/4 27/3 26/4
Birth height (cm) 33.9  3.9 34.0  3.1 33.9  3.4
Age at ligation (d) 20  11
Age at exam (d) 15  11* 6  8 3  4
Height at exam (cm) 34.8  3.8 34.6  3.3 34.2  3.2
RDS 27 26 22
Surfactant
administered
25** 20 13
Ventilation/CPAP
at exam
28/2 24/6 26/4
Inotropes before
treatment
17*** 4 0
Prophylactic
indomethacin
6 5 7
Bleeding tendencya 14**** 5 4
*p Z 0.0004, <0.0001 for Indomethacin Group and Control
Group, respectively.
**p Z 0.039 for Control Group.
***p Z 0.013, <0.0001 for Indomethacin Group and Control
Group, respectively.
****p Z 0.038, 0.015 for Indomethacin Group and Control
Group, respectively.
AGA Z adequate for gestational age; CPAP Z continuous pos-
itive airway pressure; LGA Z light for gestational age;
RDS Z respiratory distress syndrome.
a Bleeding tendency means the patient is vulnerable to bleed
in either the cranium, lung, and intestine.2.1. Study design
A retrospective case note review of the treatment of
VLBWIs with PDA was performed. Patients included in the
study were all born and/or treated at the Gifu Prefectural
General Medical Center. The indications for treatment were
analyzed in correlation with the LVDd ratio, LPA-end, and
LA/Ao ratio.
The treatment choice did not depend on the LVDd ratio.
We chose PDA ligation based on two criteria, bleeding in
the head, lungs, or intestine, and the absence of an
effective response to indomethacin treatment.
The patients receiving PDA ligation therapy were
included in the Ligation Group. Patients who underwent
indomethacin therapy were included in the Indomethacin
Group. Patients who were not treated by PDA ligation and
those who were not treated by PDA ligation or indometh-
acin therapy were included in the Control Group. These two
groups matched the ligation group with respect to sex,
gestational age, and birth body weight. Prophylactic indo-
methacin treatment was not regarded as a treatment for
PDA. We investigated the relationship between the groups
and LVDd ratio and calculated the mean and standard de-
viation (SD) of the LVDd ratio, LPA end, and LA/Ao ratio in
each group.The necessary number of neonates included in the study
was determined according to Cohen’s method,3 and that
showed 29 patients are needed to compare two groups with
a Type 1 error of 0.05 in two-sided tests and a statistical
power of 0.85, when the absolute difference divided by SD
is presumed to be 0.80.
2.2. Study patients
The inclusion criteria were as follows: (1) birth weight of
1500 g or less; (2) gestational age less than 30 weeks; (3)
patients with no congenital heart disease and no evidence
of coronary artery lesions as determined by echocardio-
gram; and (4) patients who survived.
Only VLBWIs who were born from February 1999 to
February 2012, at the Gifu Prefectural General Medical
Center were included in the study.
The characteristics of the patients are shown in Table 1.
The Ligation Group consisted of 30 neonates who under-
went PDA ligation. The Indomethacin Group consisted of 30
neonates treated with indomethacin alone; and the Control
Group consisted of 30 neonates who were treated with
palliative therapies but did not receive radical treatments.
All groups were matched by sex, gestational age, and birth
weight.
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The two-dimensional echocardiographic studies were per-
formed using the iE33 or Sonos 5500 apparatus (Philips Ul-
trasound, Bothell, WA, USA) in the left parasternal short-
axis view at the chordae tendinae level immediately below
the mitral valve with a 12e4 MHz transducer or a
7.5e5.5 MHz transducer, respectively, at rest. LVDd was
measured as the distance between the endocardial surface
of the intra-ventricular septum and the left ventricular
posterior wall at the QRS complex onset on the electro-
cardiogram by M-mode recordings. We also measured PDA
size. Each dimension was measured by the “center
convention”, i.e., using the middle bright contour
excluding the inner and outer areas, with calibrated elec-
tronic calipers.1
All measurements were performed by two observers
(HN, DT). The interobserver error was 4.5%, and the intra-
observer errors were 3.2% and 4.1%, respectively, calcu-
lated on the basis of data from 30 participants. The final
values were obtained from an average of more than three
successive beats.
2.4. Statistical analyses
The F-test and Student t test were used to determine the
differences in sample variance and means of two cate-
gories, respectively. Bonferroni correction was used to
determine statistical equivalence of means in more than
the three groups. The chi square analysis was used to
ensure statistical equivalence of the occurrence rates of
the two categories. A p value < 0.05 was considered sta-
tistically significant.
3. Results
3.1. Patient characteristics and treatments
The characteristics of the 90 patients are shown in Table 1.
The indication for ligation therapy was either no or
minimal effectiveness of indomethacin in 25 of 30 patients
in the Ligation Group. Indomethacin was not administered
to the remaining five patients because of intracranial
bleeding. The DA was closed by the end of the first
consecutive indomethacin administration in 18 of 30 pa-
tients in the Indomethacin Group. Repeat indomethacin
treatment was necessary for the other 12 patients, and the
therapy was not fully effective for two of the 12 patients.
Closed DA was confirmed in the 90 patients before
discharge.
3.2. Distribution of the LVDd ratio in each group
The distribution of the LVDd ratio in each group is shown in
Figure 1. The means and SDs of the LVDd ratio in the
Ligation Group, Indomethacin Group, and Control Group
were 142  16% (range, 122197%), 121  9% (range,
106142%), and 105  8% (range, 86122%), respectively.
There were significant differences (p < 0.0001) between
any two of the three groups. The ratios of patientsexceeding 130% in the LVDd ratio were 87% (26/30) and 20%
(6/30) in the Ligation Group and the Indomethacin Group,
respectively. The ratios of patients with less than 115% in
the LVDd ratio were 17% (5/30), and 90% (27/30) in the
Indomethacin Group and the Control Group, respectively.
3.3. Comparison of LVDd ratio with end-diastolic
left pulmonary artery flow and LA/Ao ratio
The distributions of LPA end and LA/Ao ratio in the three
groups are shown in Figure 1. The means and SDs of LPA end
in the Ligation Group, Indomethacin Group, and Control
Group were 25  12, 14  12, and 5  8, respectively. There
was a significant difference (p < 0.001) between any two of
the three groups.
The means and SDs of LA/Ao ratio in the Ligation Group,
Indomethacin Group, and Control Group were 1.82  0.31,
1.40  0.31, and 1.20  0.22, respectively. There was a
significant difference (p < 0.001) between any two of the
three groups. However, the distribution of values in the
latter two categories was wider than that of the LVDd ratio,
and overlapping data were observed in many patients.
3.4. Indications for PDA ligation
The inotropic treatments after PDA are shown in Table 2.
Catecholamine and/or vasodilator supplementation was
needed by most patients (25/30) because of decreased EF
or systemic hypertension after the operation. This indicates
that approximately 83% of the patients in the Ligation
Group were in preload and/or afterload remodeling failure
after the operation. Moreover, because patients of the
Ligation Group had a bleeding tendency or indomethacin
ineffectiveness, our definitions for the selection of ligation
therapy were almost always appropriate.
4. Discussion
Although the indications for the treatment of VLBWIs with
PDA have been studied extensively, there are currently no
clear guidelines for the treatment of these patients. This can
be partly attributed to the difficulty of establishing criteria to
decide disease severity. Several criteria are currently used to
determine the optimal treatment of VLBWIs with PDA,
includingLPAend, LA/Ao ratio, LVOto superior venacavaflow
(SVC) ratio (LVO/SVC), PDA size or its flow, PDA/LPA ratio, left
ventricular output (LVO) to right ventricular output (RVO)
ratio (LVO/RVO) determined by echocardiography, increased
cardiothoracic ratio on the chest X-ray, increased heart rate,
bounding pulse, decreased urinary output, and increased
brain natriuretic peptide value. However, no previous study
has reported a confirmed criterion for determining the man-
agement of VLBWIs with PDA as some of the criteria require
special techniques or the data show very wide variance or are
within the normal range in patients with significant PDA.
Because of the ambiguous criteria involved in the treatment
(mentioned above), deciding the appropriate treatment
approach is difficult.
Clinical symptoms, electrocardiography, and chest X-ray
are regarded as neither accurate nor specific.4,5 Although
echocardiography is commonly used to evaluate PDA
Figure 1 Distribution of the LVDd ratio, the end-diastolic flow of left pulmonary artery, and the LA/Ao ratio. The LVDd ratio is the
measured LVDd divided by the normal LVDd derived from the equation. LA/Ao Z the ratio of left atrium diameter divided by
ascending aorta diameter; LVDd Z left ventricular end-diastolic dimension.
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studies.
Hojjar et al6 reported that LVO/SVC was the most
appropriate criterion and that LA/Ao, DA diameter, mean,
and LPA end were accurate and easy to measure compared
with left ventricular output divided by superior vena cava
flow (LVO/SVC) in 23 neonates. However, LVO/SVC mea-
surement requires a special technique, and LA/Ao is
considerably influenced by the three-dimensional shape of
the LA, which varies significantly between patients. The
LPA end also has wide variance as shown in the present
study. Condo` et al7 reported that the size of the DA and the
flow through it were both appropriate for evaluating PDA
severity in 97 extremely low birth weight infants (ELBWI).
The DA size estimation is often difficult because it is not a
simple straight vessel but has a complex shape. There was
no apparent relation between the DA size and LVDd ratio
(Figure 2). Importantly, flow volume through the DA de-
pends on two parameters, the diameter of the DA at the
narrowest point and the pressure gradient between the
aorta and the pulmonary artery. The blood flow through the
DA is variable, as the flow is influenced not only by the
pressure gradient, but also the angle between the Doppler
echocardiography echo beam and blood flow. Ramos et al8
assessed 115 ELBWIs and reported that a moderate to largeTable 2 Characteristics of patients after treatment.
Groups Ligation Indomethacin Control
Catecholamines 22 4 0
Vasodilators 6 0 0
At least one therapy 25* 4 0
*p < 0.0001 for Indomethacin Group and Control Group.PDA determined from the PDA/LPA ratio at or before days
after birth can identify neonates <27 weeks’ gestation who
subsequently require PDA closure. However, this study
assessed the criteria for treatment only in neonates <27
weeks’ gestation. Phillipos et al9 reported that LVO/RVO
was an appropriate measure of PDA severity. These authors
determined that the value of the LVO minus the RVO equals
the flow through the DA. However, because the flow
through the oval foramen influences RVO in premature
neonates, the formula is not always applicable.4 Further-
more, previous reports have not included a sufficient
number of patients for an accurate evaluation.
Although the evaluation of neonates using the criteria
mentioned above can detect statistically significantFigure 2 Relationship between the DA size and the LVDd
ratio. No proportional relationship was observed between the
DA size and the LVDd ratio.
Figure 3 Treatment algorithm for VLBWIs with PDA. Dotted
lines show alternative ways to the primary choices.
ICH Z intra-cranial hemorrhage.
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PDA, this is only one of the requirements for determining
treatment. The important criterion used should have good
sensitivity and specificity in practical use, in other words,
the ideal criterion is associated with few exceptions and
can be measured at any institution. We assessed two
representative conventional criteria that have been used to
determine the severity of PDA, LPA end and LA/Ao ratio.
Although these criteria showed statistical significance for
determining the therapy for PDA, the data obtained using
these methods as indexes were associated with several
exceptions.
4.1. The superiority of the LVDd ratio as a criterion
Nagasawa1 reported novel regression equations for the
determination of LVDd in premature neonates. The LVDd in
PDA patients is commonly increased because of its
extended pulmonary flow, as a consequence of the flow
volume through the DA. Therefore, LVDd measurement
should be a useful criterion for determining treatment in
VLBWIs with PDA, which are characterized by increased left
ventricular end-diastolic volume. We estimated that the
measured LVDd divided by the normal LVDd (LVDd ratio)
might be the most appropriate index, which can be
measured at most institutions without the need for expert
personnel or special techniques.
The LVDd ratio was assessed in VLBWIs with PDA retro-
spectively. We selected 30 patients who had undergone DA
ligation, and the number of patients necessary for an ac-
curate assessment was determined according to Cohen.3
We also selected VLBWIs treated using indomethacin and
patients who had not received radical therapy for PDA. Our
results showed that the LVDd ratio has good sensitivity
(86%) and specificity (84%) for disease staging to determine
the need for PDA ligation in VLBWIs.
4.2. Calculation of cut-off index for decision-
making
The cut-off index to evaluate the indications for ligation
operation and indomethacin therapy in PDA patients was
investigated.
Qp/Qs >2.0 is the standard indication volume ratio to
operate patients with ventricular septal defect.10 An LVO/
RVO ratio close to 2 was reported to be associated with
increased intraventricular hemorrhage and periventricular
leucomalacia.9 The increase in LVDd when the LV is
enlarged to twice its volume has not been determined. We
measured the conventional fractional shortening (FS) and
the FS of the long dimension (Lg-FS) in the LV in 155 normal
full-term neonates. The mean Lg-FS/FS ratio was 0.69,
when the increased LVDd value is defined as “x”, the
equation is as follows: (1þx)2  (1þ0.69x)Z 2; xZ 0.29.
We calculated that the cut-off value of the LVDd ratio for
DA ligation was 130% of the normal ratio.
The criterion value to administrate indomethacin was
calculated in twoways.When Qp/QsZ 1.5 and the LVDd ratio
was defined as “y”, the equation was (1 þ y)2 
(1þ0.69  y) Z 1.5; y Z 0.16. The mean LVDd ratio in the
Indomethacin Group minus its SD was 112% and that of theControl Group plus its SD was 113%. The cut-off value of the
LVDd ratio for indomethacin treatmentwas 115%of thenormal
value.
4.3. Algorithm for the assessment and treatment of
VLBWIs with PDA
An algorithm for the assessment and treatment of VLBWIs
with PDA was proposed and is shown in Figure 3.
An LVDd ratio of 130% of the normal value or higher in-
dicates the need for PDA ligation. If the LVDd ratio is be-
tween 115% and 130%, indomethacin treatment should be
initiated. In cases in which indomethacin treatment is not
effective or contraindicated in patients with intracranial
hemorrhage, DA ligation should be performed. If the ratio is
less than 115%, the patient should be treated with con-
ventional therapy.
Koch et al reported that at least one-third of neonates
with a birth weight of 1000 g or less had spontaneous DA
closure and did not need medical treatment.11 Previous
reports have shown that the prognosis of patients with
indomethacin treatment is not necessarily affirmative,12e15
and adverse effects have been reported in association with
its use, which suggests that indomethacin administration
should be avoided whenever possible. The indication of
indomethacin treatment should be based on both different
indexes and physiological symptoms.
LVDd ratio as a criterion for treatment has some limi-
tations. Differences in the measurement of the LVDd ratio
according to sex, race, institution, and equipment have not
been determined. The ratio should be applied carefully
within 24 hours after birth owing to its elliptic shape in the
short axis view of the LV.
A prospective study analyzing the LVDd ratio will be
performed in the future.
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